Loading
A phase 1/2 trial of Larotrectinib in advanced solid tumours, run by Bayer, active and no longer recruiting.
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children is a phase 1/2 interventional study registered as NCT02637687 by Bayer, with 154 participants enrolled, started 2015-12-16 and due to reach its primary completion in 2024-07-20. Interventions recorded: Larotrectinib (Vitrakvi, BAY2757556).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Bayer, Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Bayer, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/